Gayle Keller
Family · Falls City, NENPI 1508805391
Payments from drug & device makers
Across 151 payments — averaging $13.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$864
- Amgen$392
- Otsuka America Pharmaceutical, Inc.$151
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$129
- Neurocrine Biosciences, Inc.$108
- Novo Nordisk$87
- plus $362 from 13 others
What the payments were for
- Food & beverage$2,093100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 70 | $864 |
| Amgen | 30 | $392 |
| Otsuka America Pharmaceutical, Inc. | 8 | $151 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 8 | $129 |
| Neurocrine Biosciences, Inc. | 7 | $108 |
| Novo Nordisk | 5 | $87 |
| Johnson & Johnson | 3 | $52 |
| Axsome Therapeutics, Inc. | 3 | $44 |
| Pfizer | 3 | $42 |
| Vanda Pharmaceuticals Inc. | 2 | $37 |
| Sunovion Pharmaceuticals Inc. | 2 | $36 |
| Teva Pharmaceuticals USA, Inc. | 2 | $28 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $25 |
| Alkermes, Inc. | 1 | $20 |
| Nevro Corp. | 1 | $17 |
| Biogen | 1 | $17 |
| Acadia Pharmaceuticals Inc | 1 | $16 |
| Lilly USA, LLC | 1 | $15 |
| Boehringer Ingelheim | 1 | $13 |
How this compares
$2,093 in reported general payments places this provider in the 85th percentile of 809 family providers in Nebraska.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VraylarCariprazine Hcl | 99 | $122,761 |
| Abilify MaintenaAripiprazole | 37 | $104,406 |
| CaplytaLumateperone Tosylate | 13 | $21,037 |
| RexultiBrexpiprazole | 20 | $13,620 |
| LinzessLinaclotide | 22 | $12,700 |
| Lurasidone Hcl | 23 | $9,702 |
| VyvanseLisdexamfetamine Dimesylate | 19 | $7,358 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 12 | $5,720 |
| Vilazodone Hcl | 43 | $4,984 |
| Lisdexamfetamine Dimesylate | 19 | $4,255 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 17 | $4,130 |
| Methylphenidate ErMethylphenidate Hcl | 15 | $1,859 |
| Duloxetine Hcl | 92 | $1,675 |
| Clozapine | 15 | $1,604 |
| Aripiprazole | 17 | $1,546 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVraylar, Linzess | $864 | $135,462121 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti | $151 | $118,02657 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $129 | $21,03713 claims |
| Lilly USA, LLCOlanzapine | $15 | $42622 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 809 family providers in Nebraska.
Other family in Falls City
- Kylee MeyerFalls City$4K
- Chantel CollierFriend$257K
- Stephanie SimonOmaha$157K
- Rebecca NewberryOmaha$156K
- Michelle BrtekzwienerNorfolk$59K
- Angela CraigOmaha$35K
- Laura FalconeOmaha$26K
- Ladeana SmedlundBoys Town$21K
- Brittany MatneyOmaha$14K
- Patricia TeeterWahoo$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.